Edwards Lifesciences Corp... (EW)
NYSE: EW
· Real-Time Price · USD
76.63
0.41 (0.54%)
At close: May 28, 2025, 3:59 PM
77.35
0.94%
Pre-market: May 29, 2025, 05:22 AM EDT
Edwards Lifesciences Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgical Heart Valve Therapy Revenue | 981.3M | 999.3M | 893.1M | 889.1M | 761.8M | 841.7M | 761.6M | 807.1M | 774.9M | 785M | 826.1M | 801.2M | 787.5M | 1.01B | 838.3M |
| Surgical Heart Valve Therapy Revenue Growth | -1.80% | +11.89% | +0.45% | +16.71% | -9.49% | +10.52% | -5.64% | +4.16% | -1.29% | -4.98% | +3.11% | +1.74% | -22.08% | +20.57% | n/a |
| Transcatheter Heart Valves Revenue | 4.11B | 3.88B | 3.52B | 3.42B | 2.86B | 2.74B | 2.29B | 2.03B | 1.63B | 1.18B | 943.6M | 707.7M | 552.1M | n/a | n/a |
| Transcatheter Heart Valves Revenue Growth | +5.83% | +10.28% | +2.80% | +19.78% | +4.36% | +19.73% | +12.80% | +24.48% | +37.97% | +25.08% | +33.33% | +28.18% | n/a | n/a | n/a |
| Transcatheter Mitral And Tricuspid Therapies Revenue | 352.1M | 197.6M | 116.1M | 86M | 41.8M | 28.2M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Transcatheter Mitral And Tricuspid Therapies Revenue Growth | +78.19% | +70.20% | +35.00% | +105.74% | +48.23% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe Revenue | 1.32B | 1.33B | 1.17B | 1.19B | 973.6M | 941.2M | 885.1M | 831M | 749M | 717.3M | 741.4M | 616.5M | 559.7M | 574M | 879.4M |
| Europe Revenue Growth | -0.96% | +13.59% | -1.30% | +22.26% | +3.44% | +6.34% | +6.51% | +10.95% | +4.42% | -3.25% | +20.26% | +10.15% | -2.49% | -34.73% | n/a |
| Japan Revenue | 339.8M | 452.4M | 473.6M | 528.9M | 460.1M | 444.7M | 396.8M | 350.3M | 309.3M | 246.2M | 270.8M | 243.6M | 294.1M | 283.7M | 567.6M |
| Japan Revenue Growth | -24.89% | -4.48% | -10.46% | +14.95% | +3.46% | +12.07% | +13.27% | +13.26% | +25.63% | -9.08% | +11.17% | -17.17% | +3.67% | -50.02% | n/a |
| Rest Of World Revenue | 572M | 709.2M | 601.4M | 550.2M | 435.8M | 429.4M | 385.6M | 346.4M | 289.7M | 267.3M | 1.05B | 245.8M | 233.7M | 215.3M | n/a |
| Rest Of World Revenue Growth | -19.35% | +17.92% | +9.31% | +26.25% | +1.49% | +11.36% | +11.32% | +19.57% | +8.38% | -74.48% | +326.08% | +5.18% | +8.55% | n/a | n/a |
| United States Revenue | 3.21B | 3.51B | 3.13B | 2.96B | 2.52B | 2.53B | 2.06B | 1.91B | 1.62B | 1.26B | n/a | 939.6M | 812.1M | 605.6M | n/a |
| United States Revenue Growth | -8.63% | +12.01% | +5.72% | +17.73% | -0.63% | +23.23% | +7.74% | +18.07% | +27.94% | n/a | n/a | +15.70% | +34.10% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 465.7M | 491.9M | 421.4M | 450.8M | 489.7M | 478.8M | 439.6M | 468.7M | 436.3M | 411M | 377.3M | 409M | 370.3M | 424M | 364.4M | 374.5M | 330.8M | 338.5M | 307.2M | 274.9M | 307.8M | 347.2M | 306.2M | 308.5M | 280.3M | 288.1M | 269.5M | 274.9M | 256M | 266.7M | 244.6M | 243.8M | 229.6M | 233.6M | 229.6M | 228.8M | 212.7M | 222.3M | 212M | 213.9M | 202.5M |
| Selling, General, and Administrative Revenue Growth | -5.33% | +16.73% | -6.52% | -7.94% | +2.28% | +8.92% | -6.21% | +7.43% | +6.16% | +8.93% | -7.75% | +10.45% | -12.67% | +16.36% | -2.70% | +13.21% | -2.27% | +10.19% | +11.75% | -10.69% | -11.35% | +13.39% | -0.75% | +10.06% | -2.71% | +6.90% | -1.96% | +7.38% | -4.01% | +9.04% | +0.33% | +6.18% | -1.71% | +1.74% | +0.35% | +7.57% | -4.32% | +4.86% | -0.89% | +5.63% | n/a |
| Research and Development Revenue | 254.6M | 271.1M | 253.4M | 272.6M | 285.2M | 270M | 270.3M | 270.3M | 261.2M | 232.2M | 233.6M | 250.8M | 228.6M | 232.8M | 238M | 225.3M | 207M | 195.7M | 195.5M | 182.1M | 187.4M | 193.9M | 195.5M | 191.9M | 171.4M | 163.1M | 161.8M | 154.1M | 143.2M | 146.6M | 142.9M | 134.4M | 128.7M | 114.9M | 113.1M | 112.9M | 102.4M | 98.2M | 101M | 97.5M | 86.4M |
| Research and Development Revenue Growth | -6.09% | +6.99% | -7.04% | -4.42% | +5.63% | -0.11% | 0.00% | +3.48% | +12.49% | -0.60% | -6.86% | +9.71% | -1.80% | -2.18% | +5.64% | +8.84% | +5.77% | +0.10% | +7.36% | -2.83% | -3.35% | -0.82% | +1.88% | +11.96% | +5.09% | +0.80% | +5.00% | +7.61% | -2.32% | +2.59% | +6.32% | +4.43% | +12.01% | +1.59% | +0.18% | +10.25% | +4.28% | -2.77% | +3.59% | +12.85% | n/a |